Full text is available at the source.
Clinical outcomes in people with type 2 diabetes and acute kidney disease: combined SGLT2i and GLP-1RA therapy vs. monotherapy
Health outcomes in type 2 diabetes with sudden kidney problems: combined SGLT2 inhibitor and GLP-1 receptor agonist treatment compared to single treatments
AI simplified
Abstract
Among 29,269 patients, 1,591 (5.4%) received combined therapy of SGLT2 inhibitors and GLP-1 receptor agonists.
- The combined therapy group had significantly lower risks of all-cause mortality compared to SGLT2 inhibitor monotherapy (adjusted hazard ratio = 0.53) and GLP-1 receptor agonist monotherapy (adjusted hazard ratio = 0.43) after a mean follow-up of 2.4 years.
- Lower risks of major adverse kidney events were observed in the combined therapy group compared to SGLT2 inhibitor monotherapy (adjusted hazard ratio = 0.70) and GLP-1 receptor agonist monotherapy (adjusted hazard ratio = 0.45) after a mean follow-up of 2.7 years.
- The risk of major adverse cardiovascular events was similar across all treatment groups.
- The combined therapy group had a higher risk of hypoglycemia (adjusted hazard ratio = 1.51) and diabetic retinopathy (adjusted hazard ratio = 1.59) compared to the SGLT2 inhibitor monotherapy group.
AI simplified